1
40
6
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1200/jco.2001.19.18.3798" target="_blank" rel="noreferrer noopener">http://doi.org/10.1200/jco.2001.19.18.3798</a>
Pages
3798–3800
Issue
18
Volume
19
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Ipsilateral breast tumor recurrence after lumpectomy: is it time to take the bull by the horns?
Publisher
An entity responsible for making the resource available
Journal of Clinical Oncology
Date
A point or period of time associated with an event in the lifecycle of the resource
2001
2001-09-15
Subject
The topic of the resource
Adult; Female; Prognosis; Combined Modality Therapy; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence; Lumpectomy; Breast Neoplasms – Pathology; Breast Neoplasms – Surgery; Breast Neoplasms – Therapy; Local – Pathology; Local – Surgery; Local – Therapy
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P; Mamounas E P
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1200/jco.2001.19.18.3798" target="_blank" rel="noreferrer noopener">10.1200/jco.2001.19.18.3798</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2001
Adult
Breast Neoplasms – Pathology
Breast Neoplasms – Surgery
Breast Neoplasms – Therapy
Combined Modality Therapy
Female
Journal of Clinical Oncology
Local – Pathology
Local – Surgery
Local – Therapy
Lumpectomy
Mamounas E P
Mamounas Eleftherios P
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplasm Recurrence
Prognosis
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
1–8
Issue
2
Volume
6
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling.
Publisher
An entity responsible for making the resource available
Clinical advances in hematology & oncology : H&O
Date
A point or period of time associated with an event in the lifecycle of the resource
2008
2008-02
Subject
The topic of the resource
Adult; Female; Humans; Middle Aged; Genotype; Clinical Trials as Topic; *Gene Expression Profiling; *Breast Neoplasms/diagnosis/genetics/therapy; Breast Neoplasms/classification/*drug therapy/*genetics/surgery; Gene Expression Profiling/*methods; Polymerase Chain Reaction/methods; Tamoxifen/therapeutic use; Receptors; Antineoplastic Agents; Adjuvant; Chemotherapy; Adjuvant/methods; Estrogen/analysis; Hormonal/therapeutic use
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P; Budd G Thomas; Miller Kathy D
Description
An account of the resource
Advances in breast cancer research have confirmed that this malignancy is not a single disease, but rather a collection of genetically distinct diseases with different treatment requirements. In recent years, several studies have confirmed the clinical validity of the Oncotype DX breast cancer assay, not only as a way to predict recurrence but also as a tool for determining therapeutic benefit from adjuvant chemotherapy. Recently, Drs. Terry Mamounas, G. Thomas Budd, and Kathy Miller answered questions about the Oncotype DX assay that are particularly relevant to routine clinical practice. This expert dialog provides a useful update and essential clinical insights about how, why, and when community oncologists may want to incorporate this multi-gene assay into their care of breast cancer patients. In addition, sample case studies offer tangible examples of the practical application of Oncotype DX.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Breast Neoplasms/diagnosis/genetics/therapy
*Gene Expression Profiling
2008
Adjuvant
Adjuvant/methods
Adult
Antineoplastic Agents
Breast Neoplasms/classification/*drug therapy/*genetics/surgery
Budd G Thomas
Chemotherapy
Clinical advances in hematology & oncology : H&O
Clinical Trials as Topic
Estrogen/analysis
Female
Gene Expression Profiling/*methods
Genotype
Hormonal/therapeutic use
Humans
Mamounas Eleftherios P
Middle Aged
Miller Kathy D
Polymerase Chain Reaction/methods
Receptors
Tamoxifen/therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3816/cbc.2003.s.010" target="_blank" rel="noreferrer noopener">http://doi.org/10.3816/cbc.2003.s.010</a>
Pages
S10–19
Volume
4 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Neoadjuvant chemotherapy for operable breast cancer: is this the future?
Publisher
An entity responsible for making the resource available
Clinical breast cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
2003-04
Subject
The topic of the resource
Female; Humans; Time Factors; Randomized Controlled Trials as Topic; Biopsy; Polymerase Chain Reaction; Evidence-Based Medicine; Europe; Breast Neoplasms/*drug therapy/*surgery; *Antineoplastic Combined Chemotherapy Protocols; Neoadjuvant Therapy/*methods/*standards; Neoplasm Staging/methods; Sentinel Lymph Node Biopsy/methods; Clinical Trials; Chemotherapy; Biological Markers; Breast Neoplasms – Drug Therapy; Breast Neoplasms – Surgery; Adjuvant – Methods; Breast Neoplasms – Radiotherapy
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P
Description
An account of the resource
The idea of using preoperative or neoadjuvant chemotherapy in patients with operable breast cancer originated from experimental and clinical observations as well as theoretical hypotheses on tumor cell growth and dissemination. Initially, nonrandomized studies demonstrated considerable rates of clinical tumor response, low rates of pathologic complete response (pCR), and increased rates of breast-conserving procedures. However, nonrandomized studies could not address the relative efficacy of neoadjuvant versus adjuvant chemotherapy on disease-free and overall survival. Similarly, earlier randomized trials were not designed as straightforward comparisons of neoadjuvant versus adjuvant chemotherapy and therefore could not adequately address the relative efficacy of neoadjuvant versus adjuvant chemotherapy on outcome. These answers were eventually provided by larger randomized trials that directly compared neoadjuvant with adjuvant chemotherapy, which are reviewed in more detail in this article. Potential advantages and disadvantages of the neoadjuvant approach and surgical considerations in the breast and axilla after neoadjuvant chemotherapy are also discussed. Finally, several recently reported trials of neoadjuvant therapy incorporating newer agents such as taxanes in sequence with anthracycline-containing regimens have shown further increases in pCR rates. Although outcome data are not available yet from these studies, it is hoped that the observed increase in pCR rates will be associated with improved outcome. If the previously observed significant correlation between the achievement of pCR and improved outcome continues to be demonstrated with these newer regimens, it will substantially strengthen the rationale for using neoadjuvant rather that adjuvant chemotherapy in the clinical setting as well as in future research studies.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3816/cbc.2003.s.010" target="_blank" rel="noreferrer noopener">10.3816/cbc.2003.s.010</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Antineoplastic Combined Chemotherapy Protocols
2003
Adjuvant – Methods
Biological Markers
Biopsy
Breast Neoplasms – Drug Therapy
Breast Neoplasms – Radiotherapy
Breast Neoplasms – Surgery
Breast Neoplasms/*drug therapy/*surgery
Chemotherapy
Clinical breast cancer
Clinical Trials
Europe
Evidence-Based Medicine
Female
Humans
Mamounas Eleftherios P
Neoadjuvant Therapy/*methods/*standards
Neoplasm Staging/methods
Polymerase Chain Reaction
Randomized Controlled Trials as Topic
Sentinel Lymph Node Biopsy/methods
Time Factors
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1634/theoncologist.10-90002-9" target="_blank" rel="noreferrer noopener">http://doi.org/10.1634/theoncologist.10-90002-9</a>
Pages
9–17
Volume
10 Suppl 2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Can we approach zero relapse in breast cancer?
Publisher
An entity responsible for making the resource available
The oncologist
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-10
Subject
The topic of the resource
Female; Humans; Gene Expression Profiling; Prognosis; Recurrence; Disease-Free Survival; Lymph Nodes/pathology; Neoadjuvant Therapy; Aromatase Inhibitors/therapeutic use; Breast Neoplasms/mortality/pathology/*prevention & control/*therapy; Antineoplastic Agents; Adjuvant; Chemotherapy; Hormonal/*therapeutic use
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P
Description
An account of the resource
Adjuvant hormonal therapy and adjuvant chemotherapy have contributed significantly to the falling rates of breast cancer mortality. The introduction of taxanes and aromatase inhibitors in the adjuvant setting represents recent important improvements. More recently, the demonstration of significant benefit in the adjuvant setting with novel molecular targeted therapies (such as trastuzumab [Herceptin; Genentech, Inc., South San Francisco, CA, http://www.gene.com]) is already beginning to have a substantial impact on the adjuvant treatment of patients with certain tumor characteristics (i.e., HER-2 positivity). Neoadjuvant treatment represents an approach that offers an intermediate end point (i.e., pathologic complete response) that can be used as a marker of therapeutic activity. Furthermore, the use of genomic profiling is starting to replace the traditional prognostic and predictive factors currently used to estimate risks for recurrence and response to particular adjuvant therapies. These recent developments have demonstrated that the notion of approaching zero relapse in breast cancer patients is now within our reach.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1634/theoncologist.10-90002-9" target="_blank" rel="noreferrer noopener">10.1634/theoncologist.10-90002-9</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2005
Adjuvant
Antineoplastic Agents
Aromatase Inhibitors/therapeutic use
Breast Neoplasms/mortality/pathology/*prevention & control/*therapy
Chemotherapy
Disease-Free Survival
Female
Gene Expression Profiling
Hormonal/*therapeutic use
Humans
Lymph Nodes/pathology
Mamounas Eleftherios P
Neoadjuvant Therapy
Prognosis
Recurrence
The oncologist
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1245/s10434-007-9702-3" target="_blank" rel="noreferrer noopener">http://doi.org/10.1245/s10434-007-9702-3</a>
Pages
691–703
Issue
3
Volume
15
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Publisher
An entity responsible for making the resource available
Annals of surgical oncology
Date
A point or period of time associated with an event in the lifecycle of the resource
2008
2008-03
Subject
The topic of the resource
Female; Humans; Neoadjuvant Therapy; Antineoplastic Agents/*administration & dosage; Aromatase Inhibitors/*administration & dosage; Breast Neoplasms/*drug therapy/*surgery; Neoplasm Recurrence; Segmental; *Mastectomy; Adjuvant; Chemotherapy; Local/*prevention & control
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P
Description
An account of the resource
Breast-conserving surgery (BCS) is an attractive option for many patients with early-stage breast cancer, because it provides a better cosmetic outcome than modified radical mastectomy, while reducing surgical morbidity. In patients with large, operable breast tumors who are ineligible for BCS, neoadjuvant therapy is a useful option for reducing the tumor size and for increasing the proportion of candidates for BCS. In patients with endocrine-responsive tumors, neoadjuvant endocrine therapy with either tamoxifen or an aromatase inhibitor (AI; anastrozole, letrozole, or exemestane) provides an alternative to neoadjuvant chemotherapy. Clinical trials have demonstrated the superiority of neoadjuvant AIs over tamoxifen in achieving a clinical response and increasing the frequency of BCS. In addition, adjuvant endocrine therapy with AIs, whether used as initial therapy instead of tamoxifen, in a switching strategy after 2-3 years of tamoxifen, or as extended adjuvant therapy after 5 years of adjuvant tamoxifen, has been shown in several randomized clinical trials to improve disease-free survival, reduce distant metastases and, in some cases, improve overall survival. The availability of the AIs for effective and well-tolerated neoadjuvant and/or adjuvant endocrine therapy represents an important advance in breast cancer treatment, and surgeons should be familiar with these new therapeutic options.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1245/s10434-007-9702-3" target="_blank" rel="noreferrer noopener">10.1245/s10434-007-9702-3</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Mastectomy
2008
Adjuvant
Annals of surgical oncology
Antineoplastic Agents/*administration & dosage
Aromatase Inhibitors/*administration & dosage
Breast Neoplasms/*drug therapy/*surgery
Chemotherapy
Female
Humans
Local/*prevention & control
Mamounas Eleftherios P
Neoadjuvant Therapy
Neoplasm Recurrence
Segmental
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/S0039-6109(03)00032-X" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/S0039-6109(03)00032-X</a>
Pages
931–942
Issue
4
Volume
83
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Sentinel lymph node biopsy after neoadjuvant systemic therapy.
Publisher
An entity responsible for making the resource available
The Surgical clinics of North America
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
2003-08
Subject
The topic of the resource
*Neoadjuvant Therapy; *Sentinel Lymph Node Biopsy; Breast Neoplasms/*pathology/*therapy; False Negative Reactions; Female; Humans; Patient Selection; Reproducibility of Results
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P
Description
An account of the resource
As sentinel node biopsy has emerged as a possible alternative to axillary node dissection in patients with operable breast cancer, this procedure is also emerging as a possible alternative in patients who have received prior neoadjuvant chemotherapy. Initial smaller, single-institution series with the latter approach have shown significant variability in the identification rates and false negative rates resulting in inconsistent–and at times disparate–conclusions regarding the appropriateness of this technique in this group of patients. Subsequent larger, multicenter series have shown, that the identification rates and false negative rates with sentinel node biopsy after neoadjuvant chemotherapy are similar to those when sentinel node biopsy is performed after breast cancer diagnosis. Thus, it appears that the sentinel node concept is also applicable in patients who have undergone neoadjuvant chemotherapy. This observation has the potential to expand the utility of neoadjuvant chemotherapy in patients with operable breast cancer.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/S0039-6109(03)00032-X" target="_blank" rel="noreferrer noopener">10.1016/S0039-6109(03)00032-X</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Neoadjuvant Therapy
*Sentinel Lymph Node Biopsy
2003
Breast Neoplasms/*pathology/*therapy
False Negative Reactions
Female
Humans
Mamounas Eleftherios P
Patient Selection
Reproducibility of Results
The Surgical clinics of North America